Literature DB >> 15499200

Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1).

Masaya Itoda1, Yoshiro Saito, Keiko Maekawa, Hiroyuki Hichiya, Kazuo Komamura, Shiro Kamakura, Masafumi Kitakaze, Hitonobu Tomoike, Kazuyuki Ueno, Shogo Ozawa, Jun-ichi Sawada.   

Abstract

Twenty genetic variations, including seven novel ones, were found in the human SLC22A1 gene, which encodes organic cation transporter 1, from 116 Japanese individuals. The novel variations were as follows: -94C>A in the 5'-untranslated region (A of the translation start codon is numbered +1 in the cDNA sequence; MPJ6_OC1001), 350C>T (MPJ6_OC1004), IVS1-35T>C (MPJ6_OC1006), 561G>A (MPJ6_OC1010), IVS6+75C>G (MPJ6_OC1014), IVS8+108A>G (MPJ6_OC1017), and 1671_1673delATG (MPJ6_OC1020). The frequencies were 0.082 for IVS1-35T>C, 0.022 for IVS6+75C>G, 0.009 for 561G>A, and 0.004 for the other 4 variations. Among them, 350C>T resulted in the amino acid substitution Pro117Leu, which is located in the large extracellular loop between transmembrane domains 1 and 2. Also, we detected the four previously reported nonsynonymous variations, 123C>G (Phe41Leu), 480C>G (Phe160Leu), 1022C>T (Pro341Leu), and 1222A>G (Met408Val) with frequencies of 0.004, 0.086, 0.168, and 0.810, respectively.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15499200     DOI: 10.2133/dmpk.19.308

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  12 in total

1.  A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction.

Authors:  Yoshinori Shinohara; Naoto Takahashi; Kaichi Nishiwaki; Masayuki Hino; Makoto Kashimura; Hisashi Wakita; Yoshiaki Hatano; Akira Hirasawa; Yasuaki Nakagawa; Kuniaki Itoh; Hidekazu Masuoka; Nobuyuki Aotsuka; Yasuhiro Matsuura; Sinobu Takahara; Koji Sano; Jun Kuroki; Tomoko Hata; Hirohisa Nakamae; Atsuko Mugitani; Takahiko Nakane; Yasushi Miyazaki; Takenori Niioka; Masatomo Miura; Kenichi Sawada
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

2.  Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects.

Authors:  Hwa Yoon; Hea-Young Cho; Hee-Doo Yoo; Se-Mi Kim; Yong-Bok Lee
Journal:  AAPS J       Date:  2013-02-16       Impact factor: 4.009

3.  Genetic variations in influx transporter gene SLC22A1 are associated with clinical responses to imatinib mesylate among Malaysian chronic myeloid leukaemia patients.

Authors:  Siti Maziras Makhtar; Azlan Husin; Abdul Aziz Baba; Ravindran Ankathil
Journal:  J Genet       Date:  2018-09       Impact factor: 1.166

Review 4.  OCT1 and imatinib transport in CML: is it clinically relevant?

Authors:  D B Watkins; T P Hughes; D L White
Journal:  Leukemia       Date:  2015-07-09       Impact factor: 11.528

5.  Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function.

Authors:  Ligong Chen; Miho Takizawa; Eugene Chen; Avner Schlessinger; Julie Segenthelar; Ji Ha Choi; Andej Sali; Michiaki Kubo; Shinko Nakamura; Yasuhiko Iwamoto; Naoko Iwasaki; Kathleen M Giacomini
Journal:  J Pharmacol Exp Ther       Date:  2010-07-16       Impact factor: 4.030

Review 6.  Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions.

Authors:  C Arimany-Nardi; H Koepsell; M Pastor-Anglada
Journal:  Pharmacogenomics J       Date:  2015-11-03       Impact factor: 3.550

7.  Genetic analysis of OCT1 gene polymorphisms in an Indian population.

Authors:  Gurusamy Umamaheswaran; Ramakrishnan G Praveen; Annan S Arunkumar; Ashok K Das; Deepak G Shewade; Chandrasekaran Adithan
Journal:  Indian J Hum Genet       Date:  2011-09

8.  Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1.

Authors:  Tina Seitz; Robert Stalmann; Nawar Dalila; Jiayin Chen; Sherin Pojar; Joao N Dos Santos Pereira; Ralph Krätzner; Jürgen Brockmöller; Mladen V Tzvetkov
Journal:  Genome Med       Date:  2015-06-18       Impact factor: 11.117

9.  Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan.

Authors:  Shinsuke Noguchi; Chiaki Nakaseko; Kaichi Nishiwaki; Hitoshi Ogasawara; Kohshi Ohishi; Michihide Tokuhira; Masaaki Noguchi; Hideo Kimura; Hiroshi Handa; Kinuko Mitani; Masatomo Miura; Hisashi Wakita; Naoto Takahashi
Journal:  Int J Hematol       Date:  2018-04-30       Impact factor: 2.490

Review 10.  Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications.

Authors:  Hermann Koepsell; Katrin Lips; Christopher Volk
Journal:  Pharm Res       Date:  2007-05-01       Impact factor: 4.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.